← Back to all trials
Completed
NCT05434325
TESTING -ON Post-Trial ObservatioNal Cohort Study
Conditions: IgA Nephropathy, ESRD, Glomerulonephritis, Kidney Diseases
Sex: All
Ages: 18 Years – 100 Years
Healthy volunteers: No
Enrollment: 211
Sponsor: The George Institute
Location: Nepean Hospital Kingswood New South Wales
Summary
The primary aim of this study is to extend follow up of TESTING study participants and to assess the long-term effects of a 6-9-month course of oral methylprednisolone on End Stage Kidney Disease (ESKD), according to dose (full-dose vs reduced-dose), ethnicity (Chinese vs other) and kidney function (eGFR above and below 60 mL/min/1.73m2).
Eligibility Criteria
Inclusion Criteria:
1\) Only participants who were randomised into the TESTING trial
Exclusion Criteria
1. Participants who have reached kidney failure requiring maintenance dialysis or kidney transplantation during the TESTING trial
2. Participants who died during the TESTING trial
3. Participants who had withdrawn their consent during the TESTING trial
4. Participants who are unable to provide consent for some other reason
Source: ClinicalTrials.gov (NCT05434325). StuddyBuddy aggregates publicly available trial information.
